Glaukos Earnings Call Transcripts
Fiscal Year 2026
-
The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability.
Fiscal Year 2025
-
Record 2025 sales grew 32% year-over-year, driven by iDose TR and strong U.S. glaucoma performance. 2026 guidance targets $600M–$620M in net sales, with continued growth expected from iDose TR and the Epioxa launch, despite anticipated volatility during the Photrexa transition.
-
Management highlighted a strategic shift toward pharmaceuticals, with iDose and Epioxa driving growth. iDose’s clinical success is tempered by ongoing reimbursement challenges, while Epioxa targets rare disease with a specialized approach. Financials show progress toward profitability and operating leverage.
-
Record quarterly revenue and margin expansion were driven by strong iDose adoption and robust growth across all franchises. Epioxa’s launch is set for 2026 with a focus on broad access, while ongoing payer and regulatory engagement supports long-term growth.
-
Epioxa pricing reflects years of investment and aims to maximize patient access, with 2026 seen as a transition year before growth resumes. iDose is positioned as the larger long-term opportunity, with reimbursement expansion and payer education as key drivers. Confidence in both products' pricing and market potential remains strong.
-
Record Q3 revenues and raised guidance highlight strong momentum, with iDose and EPIAXA positioned as major growth drivers. Market access and physician adoption are expanding, while significant investments in R&D and commercial infrastructure support long-term profitability and innovation.
-
Record Q3 sales and raised 2025 guidance reflect strong iDose TR adoption and global glaucoma growth. FDA approval of Epioxa sets up a major corneal health transition, with a staged Photrexa phase-out and significant investments in patient access and education.
-
Management anticipates sustained 20%+ growth driven by iDose TR adoption, expanding reimbursement, and Epioxa's launch, though near-term profitability is not a focus. LCD headwinds in MIGS are moderating, and international growth continues despite new competition.
-
Record Q2 sales were driven by strong iDose TR adoption and global glaucoma initiatives, prompting a raised full-year guidance. Gross margin reached 83%, and the company is preparing for Epioxa's launch while managing reimbursement and competitive headwinds.
-
A paradigm shift toward interventional glaucoma is underway, supported by new technologies, evolving practice patterns, and robust reimbursement progress for iDose. Standalone procedures and operational leverage are driving growth, while pipeline and regulatory efforts aim to expand future opportunities.
-
The conference highlighted a robust innovation pipeline, including dropless therapies like EyeDos and next-generation products for glaucoma and keratoconus. Strong clinical results, expanding market opportunities, and a solid financial position support long-term growth.
-
Reimbursement for iDose is progressing across key MACs, with commercial coverage now similar to DURYSTA. The launch is advancing steadily, with incremental sales growth expected and a stronger second half anticipated due to backlog and expanded access. Peak sales expectations have increased on a risk-adjusted basis.
-
Record Q1 net sales rose 25% year-over-year, led by iDose TR and strong U.S. glaucoma growth. Full-year guidance is reaffirmed, with iDose expectations modestly raised and LCD headwinds impacting stent revenues. Cash position remains robust at $303M+ with no debt.
-
The event highlighted robust innovation in ophthalmology, with strong clinical data and expanding product platforms driving growth. Reimbursement progress and international expansion support a positive outlook, while new therapies in glaucoma, rare disease, and retina are set to fuel future momentum.
Fiscal Year 2024
-
Record Q4 and full-year sales were driven by strong iDose TR adoption and international growth, with 2025 guidance reflecting continued momentum. U.S. non-iDose revenues face headwinds, while international and corneal segments are expected to grow modestly amid FX and reimbursement challenges.
-
MIGS and interventional glaucoma markets are expanding, with strong adoption of iStent infinite and iDose. Reimbursement progress is enabling broader access, while next-gen products and international growth are key future drivers. Gross margins are set to improve as iDose scales.
-
iDose adoption is accelerating, supported by robust training and reimbursement progress, with revenue nearly doubling in Q3 and strong growth expected. Systematic reimbursement is advancing, and copay assistance is helping drive volume. R&D investment remains a priority, balanced with a near-term focus on cash flow break-even.
-
The conference highlighted strong momentum for iDose, with robust clinical data, expanding reimbursement, and a growing addressable market. Pipeline progress includes Epioxa’s phase III success and ongoing efforts to broaden iStent indications, while international competition is rising.
-
Sequential sales growth for iDose TR is strong, driven by improved reimbursement and expanding adoption, with further acceleration expected as more MACs come online. The company is preparing for broader commercial and Medicare Advantage coverage in 2025, while pipeline products and international expansion support long-term growth.
-
Record Q3 sales grew 24% year-over-year, driven by U.S. glaucoma and iDose TR adoption. Full-year guidance was raised, with continued momentum expected in 2025 as reimbursement and market access improve. Gross margin guidance narrowed to 82%-83% for 2024.
-
Interventional glaucoma is moving toward proactive, long-term care, with iDose showing strong early adoption and positive clinical feedback. Reimbursement progress and a broad pipeline support growth, while the company balances investment and profitability goals.
-
Strong growth continues as new products like iDose and iStent infinite expand the addressable market, with the company transitioning from reimbursement to clinical adoption phases. Broader coverage and office-based procedures are expected to drive growth in 2025, while pipeline programs and international expansion remain key future opportunities.
-
Record Q2 net sales rose 19% year-over-year, driven by strong U.S. and international glaucoma growth and the ramp of iDose TR. Full-year guidance was raised, with high-20s to 30% U.S. glaucoma growth expected and cash flow break-even targeted for 2025.
-
iDose and iStent Infinite are driving a shift toward interventional glaucoma treatment, with a phased launch and expanding surgeon training. Full reimbursement for iDose is expected by Q4, supporting broader market access and margin improvement by 2025. Epioxa and a retina program highlight a robust pipeline.
-
The conference highlighted a transformative approach to glaucoma care with the launch of iDose, robust clinical results, and a diversified pipeline targeting multiple ophthalmic conditions. Strategic investments, regulatory milestones, and a strong balance sheet position the company for continued growth.